Patient and Family Information Pack
Helpful Educational Materials about Marplan® (isocarboxazid) Tablets
Click below to download and print-out two useful tools we've designed to help patients and caregivers learn more about Treatment-Resistant Major Depression* .
Patient and Family Guide Booklet
Using straightforward, non-technical language, this booklet describes Treatment-Resistant Major Depression* and how Marplan® (isocarboxazid) Tablets can help alleviate its symptoms. Safety and Dietary Guidance is also provided.
In order to view PDF Documents, you must have Adobe® Reader® installed on your computer. If you do not have it, you may download it for free at the Adobe Web Site.
Wallet-sized Diet Card
Our 'Menu for a New Beginning' is a handy card that fits into your wallet or handbag so that you can always have expert guidance on the delicious food choices to make while taking Marplan® (isocarboxazid) Tablets—and it also list the few foods you should avoid.
In order to view PDF Documents, you must have Adobe® Reader® installed on your computer. If you do not have it, you may download it for free at the Adobe Web Site.
*Treatment failure with first-line antidepressants.
Please click here to review the Marplan® (isocarboxazid) Tablets references.
Please see Full Prescribing Information including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO Inhibitors are contraindicated with certain drugs. Potential hypertensive crises may occur with foods that contain tyramine. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of treatment.
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Marplan® (isocarboxazid) Tablets or any other antidepressant in a child, adolescent or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Marplan® (isocarboxazid) Tablets is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use).
Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials.
